Details of the Drug

General Information of Drug (ID: DMXBQAM)

Drug Name
Miglitol
Synonyms Diastabol; Glyset; Plumarol; Seibule; Glyset (TN); SK-983; Bay-m-1099; Miglitol (JAN/USAN/INN); (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1]
Therapeutic Class
Hypoglycemic Agents
Affected Organisms
Humans and other mammals
ATC Code
A10BF02: Miglitol
A10BF: Alpha glucosidase inhibitors
A10B: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10: DRUGS USED IN DIABETES
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 207.22
Logarithm of the Partition Coefficient (xlogp) -2.6
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Bioavailability
60% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.7 mL/min/kg [4]
Elimination
80% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [4]
Metabolism
The drug is not metabolised []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.6811 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 1% [4]
Vd
The volume of distribution (Vd) of drug is 0.18 L/kg []
Chemical Identifiers
Formula
C8H17NO5
IUPAC Name
(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Canonical SMILES
C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O
InChI
InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
InChIKey
IBAQFPQHRJAVAV-ULAWRXDQSA-N
Cross-matching ID
PubChem CID
441314
ChEBI ID
CHEMBL6935
CAS Number
72432-03-2
UNII
0V5436JAQW
DrugBank ID
DB00491
TTD ID
D0D0ZD
ACDINA ID
D00433
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Intestinal maltase-glucoamylase (MGAM) TTXWASR MGA_HUMAN Inhibitor [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Protein S100-A10 (S100A10) OTI71243 S10AA_HUMAN Gene/Protein Processing [7]
Protein S100-A11 (S100A11) OTI57KDN S10AB_HUMAN Gene/Protein Processing [7]
Protein S100-A12 (S100A12) OTF9IIXW S10AC_HUMAN Gene/Protein Processing [7]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Gene/Protein Processing [7]
Protein S100-A6 (S100A6) OTHHPZQ8 S10A6_HUMAN Gene/Protein Processing [7]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Intestinal maltase-glucoamylase (MGAM) DTT MGAM 4.59E-01 -0.02 -0.24
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Miglitol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Pramlintide DM0EZ9Q Moderate Altered absorption of Miglitol due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [8]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Miglitol 100 mg tablet 100 mg Oral Tablet Oral
Miglitol 25 mg tablet 25 mg Oral Tablet Oral
Miglitol 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4842).
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
7 The -glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. Metabolism. 2010 Dec;59(12):1816-22. doi: 10.1016/j.metabol.2010.06.006. Epub 2010 Jul 29.
8 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.